全文获取类型
收费全文 | 2833篇 |
免费 | 183篇 |
国内免费 | 91篇 |
专业分类
儿科学 | 110篇 |
妇产科学 | 719篇 |
基础医学 | 616篇 |
口腔科学 | 7篇 |
临床医学 | 271篇 |
内科学 | 160篇 |
皮肤病学 | 11篇 |
神经病学 | 31篇 |
特种医学 | 84篇 |
外科学 | 56篇 |
综合类 | 546篇 |
预防医学 | 209篇 |
眼科学 | 2篇 |
药学 | 211篇 |
2篇 | |
中国医学 | 41篇 |
肿瘤学 | 31篇 |
出版年
2023年 | 25篇 |
2022年 | 65篇 |
2021年 | 102篇 |
2020年 | 87篇 |
2019年 | 108篇 |
2018年 | 106篇 |
2017年 | 141篇 |
2016年 | 159篇 |
2015年 | 89篇 |
2014年 | 185篇 |
2013年 | 232篇 |
2012年 | 110篇 |
2011年 | 156篇 |
2010年 | 116篇 |
2009年 | 103篇 |
2008年 | 124篇 |
2007年 | 119篇 |
2006年 | 122篇 |
2005年 | 102篇 |
2004年 | 99篇 |
2003年 | 73篇 |
2002年 | 73篇 |
2001年 | 58篇 |
2000年 | 55篇 |
1999年 | 52篇 |
1998年 | 48篇 |
1997年 | 41篇 |
1996年 | 28篇 |
1995年 | 39篇 |
1994年 | 32篇 |
1993年 | 23篇 |
1992年 | 30篇 |
1991年 | 23篇 |
1990年 | 12篇 |
1989年 | 11篇 |
1988年 | 24篇 |
1987年 | 9篇 |
1986年 | 10篇 |
1985年 | 24篇 |
1984年 | 11篇 |
1983年 | 10篇 |
1982年 | 9篇 |
1981年 | 10篇 |
1980年 | 8篇 |
1979年 | 9篇 |
1978年 | 8篇 |
1977年 | 3篇 |
1976年 | 9篇 |
1974年 | 3篇 |
1973年 | 6篇 |
排序方式: 共有3107条查询结果,搜索用时 15 毫秒
11.
人胎盘脂多糖辅助治疗支气管哮喘临床疗效观察 总被引:1,自引:0,他引:1
目的观察人胎盘脂多糖辅助治疗儿童支气管哮喘的临床疗效。方法将我院91例支气管哮喘患儿随机分成2组,治疗组46例,采用综合疗法,发作期应用沙丁胺醇、普米克令舒、氨茶碱治疗,缓解期肌内注射人胎盘脂多糖、气雾吸入倍氯米松;对照组45例,发作期用沙丁胺醇、普米克令舒、氨茶碱治疗,缓解期气雾吸入倍氯米松。结果治疗2周后治疗组、对照组对改善喘息、咳嗽症状比较,差异有显著性意义(P<0.05)。随访1年,治疗组复发率与对照组比较,差异有显著性意义(P<0.05)。结论人胎盘脂多糖辅助治疗支气管哮喘疗效确切,复发率低,值得临床推广应用。 相似文献
12.
用高速离心、分段盐析、亲和层析、超滤和阴离子交换层析法,从牛胎盘中分离纯化出一种肝细胞生长因子。结果表明,此因子的最终得率为0.005mg/g牛胎盘,其分子量约为99000u,它能强烈刺激原代培养大鼠肝细胞的DNA合成。提示利用自制的亲和层析凝胶,通过此提纯流程可以得到一种肝细胞生长因子。 相似文献
13.
目的探讨黄芪丹参复方成分提高胎盘血供的分子机制,为临床有效防治胎盘血供不足所致妊娠并发症提供思路。方法提取分离黄芪、丹参复方成分,运用NOS(一氧化氮合酶)阻滞剂L-精氨酸甲酯(L—NAME)建立一氧化氮合成阻滞大鼠模型,ELISA法检测妊娠18d大鼠血浆IL-1、IL-10水平。以及胎盘超微形态学变化,大鼠血压、尿蛋白变化,以及仔鼠重、肝重、脑重、胎盘重等。结果一氧化氮合成阻滞模型组IL-1含量明显高于空白组(P〈0.01),经黄芪丹参注射液治疗后,血浆IL-1水平比模型组降低(P〈0.05);模型组IL-10含量较空白组低(P〈0.01),中药组血浆IL-10水平高于模型组(P〈0.05);胎盘形态学、血压、尿蛋白以及仔重、仔肝重、脑重等均有显著差异(P〈0.05,P〈0.01)。结论黄芪丹参复方成分可能对妊娠早期母-胎界面免疫平衡具有调控作用,通过促进局部生理抑制性免疫反应增强和杀伤、排斥免疫反应减弱,从而有利于母胎循环构建,维持胎盘血液供应。 相似文献
14.
THE PHYSIOLOGY OF PRE-ECLAMPSIA 总被引:2,自引:0,他引:2
Mark A. Brown 《Clinical and experimental pharmacology & physiology》1995,22(11):781-791
1. Pre-eclampsia is a multisystem disorder of human pregnancy with a genetic predisposition. It occurs more commonly in first pregnancies and primarily affects maternal renal, cerebral, hepatic and clotting functions while elevating blood pressure. The foetus is affected through placental insufficiency arising from abnormal ‘placentation’, that is, failure of adequate trophoblast invasion of maternal vasculature, and possibly from abnormal autacoid production. 2. Pre-eclampsia is caused by the placenta; delivery of the placenta is the only known cure. Its manifestations are considered secondary to organ hypoperfusion which arises as a result of vasoconstriction, intravascular coagulation and reduced maternal blood volume. 3. Current hypotheses propose that pre-eclampsia is due to widespread maternal endothelial cell damage, perhaps secondary to a cytotoxic factor released by the placenta. This hypothesis has gained wide acceptance, but scientific evidence is lacking. 4. Defining the abnormal balance of vasoactive factors in pre-eclampsia has proved a difficult task. There is enhanced pressor reactivity to infused angiotensin 11 (AII) despite reduced plasma concentrations of AII, renin and aldosterone. Prostacylclin production appears reduced, and the balance of thromboxane/prostacyclin favours vasoconstriction and platelet aggregation. There is no convincing evidence for enhanced endothelin or reduced nitric oxide production. Plasma concentrations of atrial natriuretic peptide are paradoxically elevated in the face of plasma volume contraction. An intriguing observation, which remains unexplained, is why some vascular beds are affected predominantly in one patient (eg. hepatic ischaemia) while another has a similar degree of hypertension but involvement of a different organ system (eg. renal insufficiency yet normal liver function). 5. Volume homeostasis is disturbed with redistribution of intravascular volume to the interstitial fluid space due to increased capillary permeability and in some cases reduced plasma oncotic pressure. This redistribution is not always clinically apparent as peripheral oedema. Whether this change in volume is compensated for by venoconstriction and maintenance of adequate cardiac output is undetermined. 6. Improved understanding of the pathophysiology of pre-eclampsia is necessary to allow better clinical management of this serious disorder. 相似文献
15.
Objective: To investigate a possible role of apoptosis in the pathophysiologic mechanisms of PIH ( pregnancy-induced hypertension syndrome). Methods: In this study, placental samples were obtained from 16 uncomplicated third-trimester pregnancies and from 16 cases of PIH. We used light microscopy, electron microscopy to identify apoptosis. Light microscopy was used to quantify their incidence of apoptosis. Electron microscopy was used to confirm the occurrence of apoptosis. Results: Apoptosis has been conclusively demonstrated within human third-trimester placental tissue. Medians and interquartile ranges of normal placenta (n = 16) was 0. 12% (0. 08% -0. 19% ) ; Medians and interquartile ranges of PIH group (n = 16) was 0. 37% (0. 15% -0.49% ). Compared to normal placentas, the incidence of apoptosis was higher in placentas from gestations complicated by PIH ( P < 0. 05 , T'-test). Conclusion: Placental apoptosis increases significantly in PIH, and it may play a role in the pathophysiologic mechanisms 相似文献
16.
中西医结合治疗慢性盆腔炎100例疗效观察 总被引:2,自引:1,他引:1
目的:采用中西医结合治疗慢性盆腔炎,减少复发,提高治愈率。方法:对我院门诊患者100例采用胎盘组织液肌注,金钢藤胶囊口服,并用我院自制中药妇炎肠疗液灌肠。结果:临床显效40例,有效56例,无效4例,总有效率96%。结论:中西医结合治疗慢性盆腔炎疗效满意,是目前治疗慢性盆腔炎的最好方法。 相似文献
17.
一氧化氮与胚胎异常发育的相关性研究 总被引:3,自引:0,他引:3
为了解开一氧化氮(NO)是否与畸胎发生有关这一谜团和进一步阐明砷致畸作用机理,本实验应用诱生型NO合成酶(iNOS)组织化学、扫描电镜(SEM)及体内致畸试验等方法研究了砷对小鼠卵黄囊胎盘(YSP)和胚胎发育的影响。结果表明YSP细胞iNOS表达与砷浓度之间存在明显的剂量—反应关系(P<0.05);SEM观察可见YSP内皮层和间皮层细胞受损;光镜下可见YSP变小、萎缩和微血管分化不良;随着染毒剂量的升高,畸胎率和死胎率亦逐步增加,最高分别达到56.8%和24.7%;畸胎的主要表现是神经管未闭,心包积液和体位异常等。研究结果率先提示过量NO与畸胎发生及致畸机理关系密切;推荐在致畸研究中iNOS可作为一种有效的生物标志物。 相似文献
18.
E. Alsat PhD J. Guibourdenche PhD D. Luton MD F. Frankenne PhD D. Evain-Brion MD PhD 《American journal of obstetrics and gynecology》1997,177(6):1526-1534
Placental growth hormone is the product of the GH-V gene specifically expressed in the syncytiotrophoblast layer of the human placenta. Placental growth hormone differs from pituitary growth hormone by 13 amino acids. It has high somatogenic and low lactogenic activities. Assays by specific monoclonal antibodies reveal that in the maternal circulation from 15 to 20 weeks up to term placental growth hormone gradually replaces pituitary growth hormone, which becomes undetectable. It is secreted by the placenta in a nonpulsatile manner. This continuous secretion appears to have important implications for physiologic adjustment to gestation and especially in the control of maternal insulin-like growth factor-I levels. Placental growth hormone secretion is inhibited by glucose in vitro and in vivo and is significantly decreased in the maternal circulation in pregnancies with intrauterine growth restriction. Placental growth hormone does not appear to have a direct effect on fetal growth because this hormone is not detectable in the fetal circulation. However, the physiologic role might also include a direct influence on placental development through an autocrine or paracrine mechanism, as suggested by the presence of specific growth hormone receptors in this tissue.(Am J Obstet Gynecol 1997;177:1526-34.) 相似文献
19.
EFFECTS OF LOSARTAN ON THE CARDIOVASCULAR SYSTEM, RENAL HAEMODYNAMICS AND FUNCTION AND LUNG LIQUID FLOW IN FETAL SHEEP 总被引:1,自引:0,他引:1
Kathleen M. Stevenson Karen J. Gibson Eugenie R. Lumbers 《Clinical and experimental pharmacology & physiology》1996,23(2):125-133
1. The angiotensin type 1 (AT1) receptor antagonist, losartan (10 mg/kg) was infused intravenously into nine chronically catheterized fetal sheep (125–132 days gestation). Losartan reduced the fetal systolic (P < 0.01) and diastolic (P < 0.01) pressor response to 5 μg angiotensin II (AngII) i.v. from 27.4 ± 1.5 to 7.4 ± 0.9 and from 17.5 ± 1.3 to 5.4 ± 0.6 mmHg, respectively, after 1h and to 6.1 ± 0.5 and 4.4 ± 0.5 mmHg, respectively, after 2h. Maternal pressor responses to 5 μg AngII i.v. were unchanged. Fetal mean arterial pressure decreased (P < 0.05) after losartan administration, but fetal heart rate did not change. 2. Fetal haematocrit increased (P < 0.05), fetal PO2 decreased (P < 0.01), PCO2 did not change and pH decreased (P < 0.01), as did plasma bicarbonate levels (P < 0.01) following administration of losartan. Thus, losartan induced a fetal metabolic acidosis. 3. Fetal placental blood flow did not change following administration of losartan. In the fetal kidney, losartan caused a decrease in vascular resistance (P < 0.01) and an increase in blood flow (P < 0.05). Glomerular filtration rate decreased (P < 0.05); thus, filtration fraction decreased (P < 0.01). There was no change in the fractional reabsorption of sodium and glomerulotubular balance was maintained. Free water clearance decreased (P < 0.01) and became negative. Urine flow decreased (P < 0.01), the excretion rates of sodium, potassium and chloride did not change, but the urinary sodium:potassium ratio decreased (P < 0.05). There was a decrease in lung liquid flow (P < 0.05) following losartan. 4. It is concluded that the fetal renin-angiotensin system (RAS) is important in the maintenance of fetal arterial pressure, the regulation of fetal renal blood flow and is essential in the maintenance of fetal glomerular function. Further, these actions of AngII are mediated via functional AT1 receptors. These effects of losartan on the fetal cardiovascular system, renal blood flow and function are similar to those observed following captopril administration. Thus, the effects of angiotensin converting enzyme (ACE) inhibition in the foetus are due to the blockade of the fetal RAS and are independent of any direct effects on bradykinin or prostaglandin levels. 相似文献
20.
目的 探究血管内皮生长因子(vascular endothelial growth factor, VEGF)、微血管密度(micro-vascular density, MVD)、辅助性T细胞17(T helper 17 cells, Th17)和调节性T细胞(regulatory T cells, Treg)与胎盘植入感染程度关系及预测预后价值。方法 选取我院收治的胎盘植入感染患者50例作为观察组,其中轻度20例,中度17例,重度13例,另选取同期未并发感染的胎盘植入患者50例作为对照组。根据妊娠结局将患者分为预后良好(n=29)与预后不良(n=21)。比较2组VEGF、MVD、Th17/Treg,分析VEGF、MVD、Th17/Treg与常规感染标志物[白细胞介素6(interleukin-6,IL-6)、C反应蛋白(C-reactive protein, CRP)、降钙素原(procalcitonin, PCT])]及胎盘植入感染程度关系,比较不同预后患者临床资料、VEGF、MVD、Th17/Treg,分析预后影响因素,评价VEGF、MVD、Th17/Treg对胎盘植入感染患者... 相似文献